Intranasal Therapeutics and Drug Delivery Systems: The Perfect Alternative to Conventional Route of Administration
The intranasal route of administration is widely accepted as effective and non-invasive option for the local and systemic delivery of several types of active pharmaceutical ingredients (API). Majority of such formulations are designed to treat chronic obstructive pulmonary disorders (COPD), asthma and other respiratory diseases. Interestingly, over the past few years, drug developers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration. Presently, intranasal formulations are being developed for a wide range of therapeutic areas, including Parkinson’s disease, hypertension, migraine and major depressive disorder.
Stakeholders Involved in intranasal therapeutics and drug delivery domain
There are 47 companies that are involved in developing close to 75. Based on our research maximum number of players are located in North America (80%), followed by Europe and Asia-Pacific & RoW (5%, each). Small companies, as well as certain large pharmaceutical organizations, have demonstrated significant participation in this domain. Amongst the total intranasal therapeutics that are involved, more than 60% are in clinical stage followed by 24% in discovery / preclinical stage. Most of the drugs (55%) are small molecules.
Millions of dollars are being invested in funding the initiatives of various players engaged in the intranasal therapeutics and drug delivery domain
Maximum number of funding (USD 2,375 million) were reported in the year 2017. This was followed by USD 1,000 million, recorded in the year 2020. It is worth highlighting that maximum number of amount invested (USD 1,116 million) were for neurological disorders. Further, most of the funding reported by intranasal therapeutics and drug delivery systems domain were secondary offerings. Given the current trend, it can be inferred that investment from secondary offerings is a key enabler for the growth in this domain.
The intranasal therapeutics and drug delivery systems market is anticipated to grow significantly, during 2022-2035
Driven by a rich development pipeline and supported by financial assistance from public funding institutes, the intranasal drug delivery systems and therapeutics market is anticipated to grow at a CAGR of over 21%, till 2035. It is worth mentioning that North America presently has the maximum share in the growth of drug delivery systems market.
For further information on this domain, check out the report –
Intranasal Therapeutics and Drug Delivery Systems
You may also be interested in the following titles:
- Peptide Therapeutics: Contract API Manufacturing Market
- Immune Checkpoint Inhibitors (PD-1 & PD-L1 Targeting Drugs)
- Artificial Intelligence in Healthcare
Our Social Media Platform